A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. - Wikidata - wikimedia - TriplyDB

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

http://www.wikidata.org/entity/Q37171168

about

RNAi-based functional profiling of loci from blood lipid genome-wide association studies identifies genes with cholesterol-regulatory function Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease Association between a literature-based genetic risk score and cardiovascular events in women In search of low-frequency and rare variants affecting complex traits Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?Insights into metabolic disease from studying genetics in isolated populations: stories from Greece to Greenland Human Knockout Carriers: Dead, Diseased, Healthy, or Improved?Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis Cardiovascular pharmacogenomics: current status and future directions Top-down proteomics in health and disease: challenges and opportunities Islet inflammation in plain sight Exome sequencing and complex disease: practical aspects of rare variant association studies The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of l Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia Genetic variants associated with fasting blood lipids in the U.S. population: Third National Health and Nutrition Examination Survey Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression Common variants associated with plasma triglycerides and risk for coronary artery disease Genetic determinants of myocardial dysfunction.Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.Loss-of-function mutations in APOC3, triglycerides, and coronary disease An Apo-14 promoter-driven transgenic zebrafish that marks liver organogenesis.Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations.PedHunter 2.0 and its usage to characterize the founder structure of the Old Order Amish of Lancaster County.The impact of rare and low-frequency genetic variants in common disease Amyloid triangles, squares, and loops of apolipoprotein C-III.Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.Gene-centric association signals for haemostasis and thrombosis traits identified with the HumanCVD BeadChip.Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry.The genetics of obesity and the metabolic syndrome.Depression, daily stressors and inflammatory responses to high-fat meals: when stress overrides healthier food choices.Genetic determinants of lipid traits in diverse populations from the population architecture using genomics and epidemiology (PAGE) study Distribution and medical impact of loss-of-function variants in the Finnish founder population.Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism.Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man.

P2860

Q21563361-DDAC320A-7930-4E9F-99EE-288664F251EE Q24611284-3C4F3620-3FB4-440B-B3FB-13DE4AE01D09 Q24613965-4EE6E34C-2449-4F13-9E79-EA806813379B Q24618492-61C94694-7C42-4767-8927-8432F0A6166E Q24651503-0B5C74F7-A8BD-4CDC-AFDE-EC03EC7C23AD Q26746279-8BC0C987-F0CF-4B72-B429-5D927A8249BE Q26753207-DD6639F5-F1B6-452A-BD87-0EBD971F6151 Q26764736-8E69021C-F44C-498D-827B-1F9EC27E0D6E Q26798151-BC43AB23-415E-42DC-BF36-1169CDCF4714 Q26801183-2D913E31-2AEC-42A0-870B-ACC97238C869 Q27002139-115BA4FC-6DF1-4F8A-A1F5-18918D9D75D4 Q27012796-AA09942C-062F-430B-84C5-34FD9B11AE4E Q27027055-CA74F897-D9EF-49B2-A6F0-26E98C6E3E6D Q28072835-FEA0D529-DC33-4396-B8C5-ED5523A1239D Q28075372-508CBE46-9357-40D6-BC92-580141DF6F7E Q28077776-7DFA8A42-56C7-4008-B058-E6CA547BDE46 Q28240856-CC88D8CD-5700-4C78-B207-848EA407856C Q28252652-74DEF967-CE35-41FE-BDFA-3CB35A37B5B2 Q28271254-0A030944-4785-44CD-B612-650C672DCDA7 Q28395880-E0B5660E-E7CB-4FEE-9428-DFD07065B5A5 Q28545029-9C30DC26-3F10-4C66-9575-879BA7CD0CED Q28659915-FFCB71F6-BB47-4538-BD63-BFE54568A86D Q30240839-242801E9-EE6F-4903-946B-0C019673C90D Q30301147-F9F55F8B-4517-4C24-90F7-587897B29770 Q30408720-A74309BC-E430-419D-8859-5AC18BBEB9FF Q31028337-3218FBFB-F6CE-4F4D-91E5-F08F626D2F4E Q33549716-AD74D025-E798-4B7D-A18D-D03532086ECC Q33569367-FDE88234-4705-47FD-9675-E84EA432F0A2 Q33613854-4E7053D5-64D3-4DDA-8E93-2333E6C8504C Q33684952-4BC2A025-D426-4699-B929-3937F584C484 Q33762970-D2C3ACB9-786C-4C91-9233-F7261DB1646A Q33792154-84668D8B-974B-4D47-B14D-74B16B14F872 Q33794493-DAD57F6D-9BD7-4F44-AB5E-D6204DEC86A0 Q33842680-35431050-9D5F-45CC-B22F-6E3143223D45 Q33886816-4A252BA9-CABA-49C6-A10B-DD169D1C8DEB Q33900800-323BA9CB-4FA9-4E51-9062-52DC915A39EF Q33954461-D5F93AD5-9351-4B7B-A0A5-6C3DB010A006 Q33981677-1E4937D8-126A-4A5D-A529-95615F1E78E3 Q34027872-836CD9E5-9A41-4095-BA94-897C1E9B67B4 Q34094985-BA0AEC26-C721-4B0C-B306-9FD4448383D2

P2860

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

http://www.wikidata.org/entity/Q37171168

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A null mutation in human APOC3 ...... and apparent cardioprotection.

@en

A null mutation in human APOC3 ...... and apparent cardioprotection.

@nl

type

label

A null mutation in human APOC3 ...... and apparent cardioprotection.

@en

A null mutation in human APOC3 ...... and apparent cardioprotection.

@nl

prefLabel

A null mutation in human APOC3 ...... and apparent cardioprotection.

@en

A null mutation in human APOC3 ...... and apparent cardioprotection.

@nl

P1433

Q37171168-48C31950-8CB7-48CA-B649-BD17F0C1581F

P1476

Q37171168-406ADCB1-5C11-44D7-A961-65C3A13AA843

P2093

Q37171168-33DB91C5-75CB-4396-BBE5-E75FD4C7907C

Q37171168-471A3ACD-F8EE-461C-B4BD-A9566464D741

Q37171168-4813E584-DD01-4E8A-8AE9-6EDDFB996C01

Q37171168-574D4796-0F4C-4215-AA68-4CC871325DBD

Q37171168-5B436DC9-13C8-4A4B-B7F6-5371229880A9

Q37171168-8BB035A3-A9A6-46C3-AC37-9DDECA13952F

Q37171168-951FB05B-0799-4D83-94FB-354D0F92C320

Q37171168-BDF760EC-D710-4557-84C9-73241F5154CB

Q37171168-D8ADA5E3-7AEB-4771-BFD5-8CF7F4A6098B

Q37171168-DFDF5F9D-7ED0-4DA7-AAB6-B6303AF69151

P2860

Q37171168-107A3EFF-B40B-4FC4-A684-A02E32013C59

Q37171168-3541CAE8-2DB1-494A-A76E-E09A87D578F4

Q37171168-4069074F-DA46-44CA-96CD-C3426B467C1F

Q37171168-42E02DCF-A0A9-449E-AFDE-DEEDFC5CA1F4

Q37171168-47AB0ADB-D830-453E-8B1C-B6C2D789DFCB

Q37171168-47ADF6C2-ACE1-4EDA-A425-F01920C7A6A5

Q37171168-52653B0C-8CD4-4C3B-845E-DB1A4D0362C7

Q37171168-539F6A08-7ABB-42FC-B8E8-1BD45B7FEDA7

Q37171168-57E2461E-029B-48FA-B4C8-EBF977B7CCE7

Q37171168-6C84FE76-51BF-4730-B69B-86C479B42B63

P304

Q37171168-F2103B64-334A-4D11-8F30-3ADD23420256

P31

Q37171168-A3CF99AB-ED58-45E1-863C-9F19050A10C9

P356

Q37171168-57F3E80A-1528-44EA-AFC5-315951BB0405

P407

Q37171168-827B70A3-39BB-450E-AE42-FBB7E148BFBB

P433

Q37171168-66DEEFFF-6E44-4C62-B712-ABB5028C28A6

P478

Q37171168-A77FACE8-9425-4D2D-98BC-5D01499E5F4F

P50

Q37171168-6CB61098-9061-4E68-9C8A-A393A8E08802

Q37171168-9E906A53-6BBA-41DA-956B-EB75EFDF7802

P577

Q37171168-8E5C9411-8B47-4F13-B61B-421A1824EC46

P5875

Q37171168-105403FF-BFFE-44E4-955E-1F296920D227

P698

Q37171168-99AE0194-A4E9-4C76-9373-504947731322

P932

Q37171168-CD3FD136-BE04-43D6-92D9-6B29B9674562

P356

SCIENCE.1161524

P1433

P1476

A null mutation in human APOC3 ...... and apparent cardioprotection.

@en

P2093

Coleen M Damcott

http://www.w3.org/2001/XMLSchema#string

Haiqing Shen

http://www.w3.org/2001/XMLSchema#string

Jeffrey R O'Connell

http://www.w3.org/2001/XMLSchema#string

John C McLenithan

http://www.w3.org/2001/XMLSchema#string

John Shelton

http://www.w3.org/2001/XMLSchema#string

Lawrence F Bielak

http://www.w3.org/2001/XMLSchema#string

Michael Miller

http://www.w3.org/2001/XMLSchema#string

Patricia A Peyser

http://www.w3.org/2001/XMLSchema#string

Richard B Horenstein

http://www.w3.org/2001/XMLSchema#string

Sandra H Ott

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of Coronary Heart Disease Using Risk Factor Categories

Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups

Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr

Apolipoprotein C-III: understanding an emerging cardiovascular risk factor

Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Amino acid sequence of human plasma apolipoprotein C-III from normolipidemic subjects

Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia

A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

P304

1702-1705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1161524

http://www.w3.org/2001/XMLSchema#string

P407

P433

5908

http://www.w3.org/2001/XMLSchema#string

P478

322

http://www.w3.org/2001/XMLSchema#string

P50

Braxton D. Mitchell

Alan R. Shuldiner

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23655250

http://www.w3.org/2001/XMLSchema#string

P698

19074352

http://www.w3.org/2001/XMLSchema#string

P932

2673993

http://www.w3.org/2001/XMLSchema#string